Skip to main content

Advertisement

ADVERTISEMENT

Lung Cancer News

News
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
09/27/2022

Yvette C Terrie

Yvette C Terrie
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide...
09/27/2022
Journal of Clinical Pathways
News
06/23/2022

Ellen Kurek

Ellen Kurek
Researchers established a multidisciplinary lung cancer clinic in a large, community-based healthcare system and conducted a prospective, comparative-effectiveness study to evaluate patients’ experiences with and outcomes of clinic care.
Researchers established a multidisciplinary lung cancer clinic in a large, community-based healthcare system and conducted a prospective, comparative-effectiveness study to evaluate patients’ experiences with and outcomes of clinic care.
Researchers established a...
06/23/2022
Journal of Clinical Pathways

Advertisement

News
05/16/2022

Ellen Kurek

Ellen Kurek
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a...
05/16/2022
Journal of Clinical Pathways
News
05/11/2022

Ellen Kurek

Ellen Kurek
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor...
05/11/2022
Journal of Clinical Pathways
News
04/05/2022

Marta Rybczynski

Marta Rybczynski
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a...
04/05/2022
Journal of Clinical Pathways

Advertisement

News
04/01/2022

Janelle Bradley

Janelle Bradley
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a...
04/01/2022
Journal of Clinical Pathways
News
04/01/2022

Janelle Bradley

Janelle Bradley
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90%...
04/01/2022
Journal of Clinical Pathways
News
05/13/2021
Study findings show the implementation of clinical care pathways resulted in improved survival for patients diagnosed with NSCLC.
Study findings show the implementation of clinical care pathways resulted in improved survival for patients diagnosed with NSCLC.
Study findings show the...
05/13/2021
Journal of Clinical Pathways

Advertisement

News
05/06/2021
For patients with relapsed SCLC, second-line, platinum-doublet chemotherapy may be beneficial over non-platinum regimens.
For patients with relapsed SCLC, second-line, platinum-doublet chemotherapy may be beneficial over non-platinum regimens.
For patients with relapsed SCLC,...
05/06/2021
Oncology

Advertisement